Copernicus Therapeutics, Inc. (CTI) is a clinical stage biopharmaceutical company and a leader in the emerging field of precision medicine and gene therapy. Through their proprietary, non-viral, nucleic acid nanoparticle platform, they are able to achieve robust gene transfer in several tissues without the immune response and limited treatment window of AAV. Combined with world-class intellectual property in plasmid design for long-term and controlled expression, CTI is poised to become a leader in the 21st century pharmaceutical industry. Current programs include: Cystic Fibrosis (Phase I/II Complete) Eye (Pre-clinical) Brain (Pre-clinical) Founded on technologies developed at Case Western Reserve University in Cleveland, Ohio, CTI has a strong connection to the growing biotechnology industry in Northeast Ohio.